Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
12 Dec, 20:00
XMUN XMUN
865. 70
+19.4
+2.29%
- Market Cap
104.2 P/E Ratio
5.2% Div Yield
6 Volume
6.64 Eps
846.3
Previous Close
Day Range
862.6 865.8
Year Range
538.1 960.5
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 54 days

Summary

LLY closed today higher at €865.7, an increase of 2.29% from yesterday's close, completing a monthly increase of 15.58% or €116.7. Over the past 12 months, LLY stock gained 15.69%.
LLY pays dividends to its shareholders, with the most recent payment made on Dec 10, 2025. The next announced payment will be in In 2 months on Mar 10, 2026 for a total of €1.73.
The last earnings report, released on Oct 30, 2025, missed the consensus estimates by -5.92%. On average, the company has fell short of earnings expectations by -3.84%, based on the last three reports. The next scheduled earnings report is due on Feb 05, 2026.
Eli Lilly and Company has completed 4 stock splits, with the recent split occurring on Oct 16, 1997.
The company's stock is traded on 16 different exchanges and in various currencies, with the primary listing on NYSE (USD).

LLY Chart

Why the Market Dipped But Eli Lilly (LLY) Gained Today

Why the Market Dipped But Eli Lilly (LLY) Gained Today

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Zacks | 3 hours ago
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025)

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025)

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher.

247wallst | 13 hours ago
Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide

Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide

Eli Lilly and Co (NYSE:LLY) has reported positive topline results from its Phase 3 TRIUMPH-4 trial evaluating its obesity treatment retatrutide in adults with obesity and knee osteoarthritis. The investigational drug, a once-weekly injectable targeting GLP‑1, GIP, and glucagon receptors, is designed to regulate appetite and metabolism through multiple hormone pathways.

Proactiveinvestors | 1 day ago

Eli Lilly and Company (LLY) FAQ

What is the stock price today?

The current price is €865.70.

On which exchange is it traded?

Eli Lilly and Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 5.2%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 7.18.

When is the next earnings date?

The next earnings report will release on Feb 05, 2026.

Has Eli Lilly and Company ever had a stock split?

Eli Lilly and Company had 4 splits and the recent split was on Oct 16, 1997.

Eli Lilly and Company Profile

Pharmaceuticals Industry
Healthcare Sector
David A. Ricks CEO
XMUN Exchange
US5324571083 ISIN
US Country
47,000 Employees
13 Feb 2026 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000